Forecast

There is no analyst data available for this company.

News Go to news feed

BACHEM: Chief Commercial Officer Torsten Wöhr leaves the company

BACHEM confirms the departure of Chief Commercial Officer Torsten Wöhr. No further details on the timing of his exit or on his successor were given in the announcement. » More on finanzen.net
BACHEM pays CHF 0.90 dividend for 2025

At its general meeting, BACHEM approved a dividend of CHF 0.90 per share for 2025, an increase of 5.88% from the previous year. A total of CHF 30.73 million will be distributed, but the total payout is nevertheless 48.77% below last year’s level. The dividend yield for 2025 is 1.50%; the share price rose 35.15% over one year (total return including dividend: 38.13%). FactSet analysts expect a dividend of CHF 1.01 for 2026 (expected yield 1.48%). » More on finanzen.net
BACHEM: 100‑franc investment five years ago would be 2.92% down today

If 100 CHF had been invested in BACHEM stock five years ago (closing price then 72.00 CHF), investors would now hold 1.389 shares worth 97.08 CHF (closing price 23 Jan 2026: 69.90 CHF). That corresponds to a loss of 2.92%. BACHEM most recently reported a market capitalization of 5.23 billion CHF; stock splits and dividends were not considered in the calculation. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Bachem Holding AG has already paid 0,98€ in dividends. The last payout was in May.

Financials

In the last quarter, Bachem Holding AG had revenue of 353,66 Mio€ and net profit of 54,46 Mio€

(EUR)	Jun 2026	YoY
Revenue	+353,66 Mio	-
Gross profit	+88,46 Mio	-
Net profit	+54,46 Mio	-
EBITDA	+89,12 Mio	-

Fundamentals

Metric	Value
Market capitalization	+6,18 Mrd€
Number of shares	74,94 Mio
52-week high/low	+112,46€ - +58,42€
Dividend yield	+1,21%
Dividends TTM	+0,98€
Beta	0,81
P/E ratio	+38,77
PEG ratio	+3,47
P/B ratio	+4,00
P/S ratio	+8,16

Company profile

Die Bachem Holding AG liefert Produkte für die Forschung, die klinische Entwicklung und die kommerzielle Anwendung an Pharma- und Biotechnologieunternehmen weltweit. Das Unternehmen befasst sich mit der Entwicklung, Produktion und regulatorischen Unterstützung von peptidischen pharmazeutischen Wirkstoffen, wie Peptid- und Oligonukleotid-NCEs (New Chemical Entities). Darüber hinaus bietet es kommerzielle NCEs und Generika sowie Dienstleistungen in den Bereichen Projektmanagement, Qualität und Regulierung, Analytik, Produktion nach guter Herstellungspraxis, Produktion in Forschungsqualität sowie Lieferung und vertikale Integration an. Das Unternehmen wurde 1971 gegründet und hat seinen Hauptsitz in Bubendorf, Schweiz. Die Bachem Holding AG ist eine Tochtergesellschaft der Ingro Finanz AG.

Name	Bachem Holding AG
CEO	Anne-Kathrin Stoller
Headquarters	Bubendorf, bl Switzerland
Website	bachem.com
Sector	Health Care
Industry	Health Care Providers & Services
IPO	07/16/2012
Employees	2.511